The comparison was mainly conducted between patients with complete remission of AML versus patients who relapsed, patients with positive or increased CD36 expression versus negative or decreased CD36 expression, but there were also comparisons with healthy individuals and people with other types of cancer. The gene discussed is CD36; the disease is cancer.